Clinical Report: Assessment of Sexual Dysfunction Rates in Cancer Patients
Overview
This systematic review and meta-analysis reveals high rates of sexual dysfunction (SD) among cancer patients, with prevalence varying significantly by cancer type and treatment modality. The findings underscore the need for improved recognition and management of sexual health issues in oncology care.
Background
Cancer is a leading cause of death globally, and its impact extends beyond physical health to include significant effects on sexual health. Sexual dysfunction is prevalent among cancer patients, yet it remains underrecognized and inadequately addressed in clinical practice. Understanding the prevalence and determinants of SD is crucial for enhancing the quality of life for cancer survivors.
Data Highlights
No specific numerical data provided in the source material.
Key Findings
Sexual dysfunction affects 86-91% of patients with prostate, breast, and gynecological cancers.
Prevalence rates of sexual dysfunction range from 53-79% in head and neck, hematologic, and colorectal cancers.
Barriers to discussing sexual health include patient reluctance and healthcare providers' lack of training.
Only 2% of patients with advanced cancer were sexually active despite 62% desiring intimacy.
Existing literature on sexual dysfunction in cancer survivors is fragmented and inconsistent.
Clinical Implications
Healthcare providers should routinely assess sexual health in cancer patients to address the high prevalence of sexual dysfunction. Training and resources are needed to facilitate open discussions about sexual health and to implement effective management strategies.
Conclusion
Addressing sexual dysfunction is essential for holistic cancer care, and this study highlights the urgent need for systematic assessment and intervention in oncology settings.
